At the presentation of the preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year 2022, Jon Stonehouse, President and CEO of BioCryst Pharmaceuticals, Inc., says:

“In our second year on the market, we more than doubled our first-year ORLADEYO sales. This continues to be an exceptional launch of an oral rare disease drug, and we expect this success to continue creating real value for patients and for shareholders this year and for many years to come.”

The number of patients on therapy at the end of 2022 was in-line with the company’s expectations as patients continued to switch to ORLADEYO in the fourth quarter. BioCryst sees continued growth in 2023 in the U.S. and around the world.
(Source: BioCryst)